Abstract: SA-PO0644
Online Continuing Medical Education Improves Clinical Insights into B-Cell-Targeted Therapies for IgAN Among Nephrologists
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Nair, Arun, Medscape Education, Newark, New Jersey, United States
- Stange, Frederick, Medscape Education, Newark, New Jersey, United States
- Blatherwick, Donald, Medscape Education, Newark, New Jersey, United States
Background
Immunoglobulin A nephropathy (IgAN) treatment is evolving rapidly with the emergence of B-cell-targeted therapies. Nephrologists face challenges in connecting novel renal biomarkers with long-term clinical data. This educational intervention aimed to enhance specialist knowledge regarding clinical correlations and pivotal trial evidence for B-cell modulating agents.
Methods
The intervention featured a 30-minute online video roundtable with expert faculty analyzing recent clinical trial data and the IgAN treatment landscape. A matched pre- and post-assessment design was utilized to measure educational impact with data collected from July 9, 2025, to October 28, 2025. Statistical significance was determined using McNemar’s test (P < .05) & Cohen’s d for effect size.
Results
A total of n = 54 nephrologists completed the assessment. The education resulted in a large effect size (Cohen’s d = 0.65).
Foundational Biomarker Knowledge: Nephrologists demonstrated a strong baseline understanding of IgAN pathogenesis, with 61% correctly identifying the correlation between B-cell-activating factor (BAFF) and proteinuria at pre-assessment.
Emerging Therapy Evidence: Knowledge regarding the long-term efficacy and durability of emerging B-cell therapies improved significantly. Post-education, 57% of nephrologists correctly identified sustained kidney function improvements through 96 weeks, compared to 28% at pre-assessment (a 104% relative increase; P < .001).
Treatment Goals and Endpoints: Specialists improved their understanding of key endpoints for novel care strategies, such as the 24-hour urine protein to creatinine ratio (UPCR). Identification of these outcome measures increased from 57% at pre-assessment to 72% at post-assessment (P < .05).
Conclusion
This online continuing medical education (CME) activity significantly improved nephrologists' ability to interpret clinical trial data, particularly regarding the durability of response for emerging B-cell therapies. While foundational biomarker knowledge is high, persistent gaps in long-term data interpretation for 43% of the cohort highlight the need for continued education to ensure clinical readiness. Strengthening these insights empowers specialists to align treatment goals with evidence-based recommendations, facilitating the confident integration of novel B-cell-targeted strategies into the IgAN care paradigm.
Acknowledgment
This education was supported by an independent educational grant from Vera Therapeutics.
Funding
- Commercial Support – Vera Therapeutics